nonalcohol
steatohepat
nash
character
fat
accumul
hepat
tissu
associ
variou
degre
inflamm
progress
fibrosi
potent
antiinflammatori
ethnopharmacolog
properti
lonicera
japonica
thunb
caprifoliacea
make
excel
sourc
novel
medicin
target
treatment
nash
aim
studi
investig
effect
l
japonica
ethanol
extract
ljee
nash
mice
mice
fed
methioninecholinedefici
diet
mcdd
eight
week
promot
develop
nash
develop
model
mice
administ
ljee
daili
via
oral
gavag
dose
mgkg
anoth
four
week
simultan
treatment
ljee
mgkgday
result
pronounc
improv
liver
steatosi
balloon
degener
inflamm
ljee
prevent
mcddinduc
plasma
level
increas
aspart
aminotransferas
alanin
aminotransferas
ljee
significantli
reduc
hepat
malondialdehyd
level
amelior
hepat
inflamm
fibrosi
mcddfed
mice
associ
downregul
cytochrom
suppress
multipl
proinflammatori
profibrot
gene
ljee
prevent
hepat
steatosi
reduc
hepat
peroxisom
acylcoa
diacylglycerol
acyltransferas
express
well
induc
proliferatoractiv
receptor
express
addit
ljee
treatment
caus
signific
reduct
phosphoryl
form
jun
ntermin
kinas
along
increas
phosphoryl
level
extra
cellular
signalregul
kinas
studi
demonstr
protect
role
ljee
amelior
nutrit
steatohepat
nonalcohol
fatti
liver
diseas
nafld
condit
excess
fat
accumul
liver
patient
histori
alcohol
abus
nafld
classifi
two
categori
simpl
steatosi
steatosi
observ
nonalcohol
steatohepat
nash
addit
steatosi
lobular
inflamm
liver
cell
injuri
observ
although
underli
mechan
diseas
progress
remain
poorli
understood
twohit
hypothesi
describ
pathophysiolog
nash
steatosi
primari
insult
sensit
liver
secondari
seriou
insult
includ
reactiv
oxygennitrogen
speci
gutderiv
endotoxin
proinflammatori
cytokin
like
tumor
necrosi
factoralpha
result
nash
develop
nash
may
develop
liver
cirrhosi
hepatocellular
carcinoma
avail
treatment
option
nash
includ
weight
loss
dietari
lifestyl
modif
use
insulin
sensit
lipid
lower
drug
furthermor
combin
approach
also
tri
manag
nash
sinc
nash
multifactori
diseas
singl
target
base
therapi
limit
implic
lonicera
japonica
thunb
caprifoliacea
also
known
japanes
honeysuckl
jin
yin
hua
ren
dong
nativ
east
asian
recogn
edibl
medicin
food
edibl
bud
flower
could
made
liquor
tea
folk
diet
time
could
use
medicin
cosmet
ornament
groundcov
constitu
plant
previous
investig
shown
contain
iridoid
glucosid
polyphenol
compound
main
polyphenol
compon
l
japonica
chlorogen
acid
caffeic
acid
flavoyadorininb
methyl
chlorogen
protocatechu
acid
make
great
contribut
special
activ
current
chines
pharmacopoeia
chlorogen
acid
offici
use
indic
compound
character
qualiti
herb
modern
pharmacolog
studi
show
l
japonica
wide
pharmacolog
action
antibacteri
antiinflammatori
antivir
antiendotoxin
antipyret
activ
sinc
lonicera
japonica
list
pharmacopoeia
peopl
republ
china
made
prepar
treat
chronic
enter
pneumonia
acut
tonsil
nephriti
acut
mastiti
leptospirosi
clinic
l
japonica
also
employ
extens
prevent
treat
seriou
viral
diseas
human
veterinari
sar
coronaviru
swine
flu
viru
chines
pharmacopoeia
flower
flower
bud
offici
use
activ
part
treat
diseas
pharmacolog
studi
demonstr
l
japonica
antifibrot
effect
rat
fibrosi
induc
dimethylnitrosamin
also
report
herbal
formula
consist
l
japonica
attenu
carbon
tetrachlorideinduc
liver
damag
rat
hepatoprotect
potenti
plant
could
consid
howev
possibl
l
japonica
could
prove
benefici
amelior
nash
previous
explor
use
diet
defici
essenti
amino
acid
methionin
cholin
wellaccept
model
induc
nash
recapitul
mani
featur
diseas
human
includ
histolog
pictur
mimic
seen
human
fibrot
disord
associ
hepat
lipid
accumul
presenc
inflamm
oxid
stress
support
applic
l
japonica
treatment
nashlik
disord
studi
investig
hepatotherapeut
effect
l
japonica
anim
model
methionineand
cholinedefici
diet
mcdd
induc
hepat
injuri
elucid
underli
mechan
involv
ciprofibr
fibric
acid
deriv
commerci
avail
drug
treatment
hyperlipidemia
document
ciprofibr
daili
oral
dosag
mgkg
effect
amelior
hyperlipidemia
hypertriglyceridem
mice
present
studi
ciprofibr
thu
use
posit
control
compar
effect
l
japonica
amelior
nash
flower
aerial
part
l
japonica
collect
ligang
township
pingtung
counti
taiwan
novemb
macroscop
microscop
examin
thinlay
chromatographi
highperform
liquid
chromatographi
hplc
use
confirm
authent
plant
materi
provid
analysi
perform
dr
tangyao
hong
depart
biotechnolog
collag
pharmaci
health
care
tajen
univers
voucher
specimen
lot
lj
preserv
laboratori
futur
refer
flower
aerial
part
l
japonica
airdri
pulver
coars
powder
mechan
grinder
pass
siev
get
powder
sampl
powder
sampl
kg
extract
room
temperatur
thrice
l
ethanol
h
orbit
shaker
make
ethanol
extract
l
japonica
ethanol
extract
ljee
evapor
dryness
reduc
pressur
complet
elimin
alcohol
lyophil
yield
approxim
g
dri
residu
ww
yield
ljee
store
use
suspend
distil
water
content
chlorogen
acid
sampl
analyz
use
agil
hplc
system
agil
technolog
inc
santa
clara
ca
usa
calibr
equat
peak
area
concentr
chlorogen
acid
r
chlorogen
acid
content
ljee
dri
extract
fourtyeight
sixweekold
male
mice
obtain
nation
laboratori
anim
center
taipei
taiwan
maintain
temperaturecontrol
room
lightdark
cycl
light
h
anim
center
food
water
provid
ad
libitum
mcdd
methionineand
cholinesuffici
diet
mcsd
purchas
dyet
inc
respect
bethlehem
pennsylvania
pa
usa
diet
contain
similar
nutrient
protein
fat
ash
fiber
except
methionin
cholin
includ
mcdd
wherea
gkg
methionin
gkg
cholin
bitartr
provid
mcsd
anim
procedur
perform
accord
guid
care
use
laboratori
anim
nation
institut
health
well
guidelin
anim
welfar
act
studi
conduct
approv
institut
anim
care
use
committe
iacuc
tajen
univers
iacuc
decemb
consum
mcdd
eight
week
group
eight
mice
dose
oral
gavag
per
day
either
ljee
dose
mgkg
volum
mlkg
distil
water
dosag
regim
select
base
previou
report
demonstr
ljee
mgkg
potenti
effect
improv
renal
function
diabet
rat
anoth
group
mcddfed
mice
n
oral
administ
ciprofibr
mgkgday
dissolv
distil
water
dose
base
studi
indic
longterm
treatment
amelior
hyperlipidemia
hypertriglyceridem
mice
vehicletr
mice
receiv
mlkg
distil
water
vehicletr
group
mcddfed
mice
n
group
mcsdfed
mice
n
treat
mlkg
distil
water
treatment
period
follow
fourweek
treatment
anim
weigh
fast
h
sacrif
intraperiton
inject
mixtur
ketamin
mgkg
xylazin
mgkg
blood
sampl
inferior
vena
cava
collect
heparin
syring
unitsml
blood
left
lobe
liver
remov
rins
physiolog
salin
store
immedi
liquid
nitrogen
assay
right
lobe
liver
fix
neutral
formalin
histolog
rel
liver
weight
liver
weight
divid
bodi
weight
blood
sampl
centrifug
min
plasma
remov
place
aliquot
analys
diagnost
kit
determin
plasma
level
total
cholesterol
tc
cat
triglycerid
tg
cat
purchas
cayman
chemic
compani
ann
arbor
mi
usa
kit
determin
plasma
alanin
aminotransferas
alt
ec
cat
aspart
aminotransferas
ast
ec
cat
concentr
purchas
teco
diagnost
anaheim
ca
usa
experiment
assay
carri
accord
manufactur
instruct
sampl
analyz
triplic
hepat
lipid
content
determin
fresh
liver
sampl
liver
g
homogen
chloroformmethanol
ml
mix
well
chloroform
ml
distil
water
ml
centrifug
min
lower
clear
organ
phase
transfer
new
glass
tube
lyophil
lyophil
powder
dissolv
chloroformmethanol
store
less
three
day
hepat
cholesterol
tg
level
lipid
extract
analyz
use
diagnost
kit
use
plasma
analysi
liver
malondialdehyd
mda
level
index
lipid
peroxid
determin
doubl
heat
method
method
base
spectrophotometr
measur
purpl
color
gener
reaction
thiobarbituricacid
tba
mda
liver
tissu
homogen
wv
mmoll
trishcl
centrifug
rpm
min
supernat
aliquot
store
assay
mda
assay
ml
trichloroacet
acid
solut
ad
ml
supernat
follow
heat
boil
water
bath
min
cool
room
temperatur
sampl
centrifug
rpm
min
ml
reaction
mixtur
transfer
test
tube
contain
ml
tba
solut
tube
place
boil
water
bath
min
cool
room
temperatur
absorb
measur
nm
concentr
mda
calcul
base
absorb
coeffici
tbamda
complex
microscop
analysi
liver
fragment
slide
stain
hematoxylin
eosin
h
e
subsequ
assess
singl
pathologist
unawar
experiment
group
histopatholog
featur
steatohepat
evalu
semiquantit
accord
valid
histolog
score
system
recommend
patholog
committe
nash
clinic
research
network
follow
steatosi
grade
lobular
inflamm
foci
foci
per
foci
per
foci
per
hepatocyt
balloon
none
balloon
cell
mani
cellspromin
balloon
measur
perform
light
microscop
attach
digit
camera
olympu
tokyo
japan
experienc
pathologist
liver
sampl
homogen
min
icecold
radioimmun
protect
assay
lysi
buffer
mmoll
tri
ph
mmoll
nacl
triton
sodium
deoxychol
sodium
dodecyl
sulfat
mgml
leupeptin
mmoll
sodium
fluorid
mmoll
sodium
orthovanad
mmoll
phenylmethylsulfonyl
fluorid
liver
homogen
centrifug
rpm
min
protein
concentr
determin
use
bradford
method
equal
protein
amount
separ
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
electrotransf
onto
polyvinyliden
difluorid
membran
block
bovin
serum
albumin
probe
primari
antibodi
extra
cellular
signalregul
kinas
erk
santa
cruz
biotechnolog
santa
cruz
ca
usa
phosphoerk
santa
cruz
ca
usa
jun
ntermin
kinas
jnk
santa
cruz
biotechnolog
phosphojnk
santa
cruz
biotechnolog
mitogenactiv
protein
kinas
cell
signal
technolog
beverli
usa
cell
signal
technolog
santa
cruz
biotechnolog
level
estim
equal
load
sampl
membran
wash
three
time
trisbuff
salin
tween
tbst
incub
h
room
temperatur
appropri
horseradish
peroxidaseconjug
secondari
antibodi
three
addit
tbst
wash
immunoreact
band
visual
enhanc
chemiluminesc
amersham
bioscienc
buckinghamshir
uk
accord
manufactur
instruct
band
densiti
determin
use
atto
densitograph
softwar
atto
corpor
tokyo
japan
experi
equal
protein
load
confirm
content
analyz
gene
express
total
rna
extract
frozen
liver
sampl
use
trizol
reagent
invitrogen
boston
usa
rna
quantifi
integr
verifi
agaros
gel
electrophoresi
use
ethidium
bromid
visual
revers
transcriptas
reaction
total
rna
per
sampl
random
hexam
primer
heat
min
quench
ice
mixtur
combin
datp
dttp
dctp
dgtp
tabl
highli
specif
measur
mrna
carri
cytochrom
cyp
tumor
necrosi
factor
tnf
transform
growth
factor
tgf
muscl
actin
sma
type
collagen
collagen
matrix
metalloproteinas
mmp
peroxisom
acylcoa
diacylglycerol
acyltransferas
proliferatoractiv
receptor
ppar
use
lightcycl
system
biorad
sampl
run
analyz
duplic
primer
design
use
primer
express
softwar
version
system
appli
biosystem
foster
citi
ca
usa
pcr
reaction
perform
use
follow
cycl
protocol
min
cycl
dissoci
curv
run
amplif
identifi
specif
pcr
product
mrna
level
normal
mrna
valu
result
express
fold
chang
threshold
cycl
ct
valu
rel
control
use
deltadelta
ct
method
ensur
amplif
specif
rtpcr
amplifi
product
subject
agaros
gel
electrophoresi
visual
confirm
presenc
singl
amplicon
expect
size
data
express
deviat
sd
statist
analys
perform
use
oneway
analysi
varianc
dunnett
rang
posthoc
comparison
use
determin
sourc
signific
differ
appropri
sigmaplot
version
systat
softwar
san
jose
ca
program
use
statist
analysi
valu
p
consid
statist
signific
mcdd
remark
decreas
mous
bodi
liver
weight
compar
mcsd
tabl
treat
mcddfed
mice
ljee
mgkgday
result
signific
effect
bodi
weight
absolut
liver
weight
rel
liver
weight
tabl
similar
result
found
mcddfed
mice
treat
ciprofibr
tabl
plasma
level
tc
tg
lower
mcddfed
mice
mcsdfed
anim
treatment
mcddfed
mice
ljee
ciprofibr
signific
effect
plasma
tc
tg
tabl
hepat
cholesterol
tg
level
significantli
higher
mcddfed
mice
compar
mice
mcsdfed
group
treatment
mcddfed
mice
ljee
mgkgday
reduc
hepat
cholesterol
tg
level
respect
compar
level
vehicletr
mcddfed
mice
tabl
hepat
level
cholesterol
tg
mcddfed
mice
receiv
ciprofibr
treatment
decreas
respect
compar
vehicletr
mcddfed
mice
tabl
plasma
alt
ast
activ
mcddfed
mice
higher
mcsdfed
group
tabl
plasma
alt
ast
activ
markedli
reduc
mcddfed
mice
treat
four
week
mgkgday
ljee
tabl
ciprofibr
treatment
also
significantli
attenu
chang
plasma
alt
ast
activ
mcd
dietf
mice
tabl
liver
section
mcsdfed
group
stain
h
e
show
normal
hepat
cell
histoarchitectur
figur
mcdd
induc
measur
hepat
steatosi
mainli
predomin
macrovesicular
pattern
mice
progress
inflamm
fibrosi
figur
hepat
steatosi
lobular
inflamm
hepatocyt
balloon
significantli
reduc
ljee
mgkgday
ciprofibratetr
group
compar
mcddonli
fed
group
figur
liver
histolog
evalu
use
nash
score
figur
vehicl
distil
water
use
prepar
test
medic
solut
given
volum
valu
obtain
group
eight
anim
group
four
week
experiment
period
p
b
p
compar
valu
vehicletr
mcddfed
mice
group
respect
hepat
level
mda
mcddfed
mice
markedli
higher
mcsdfed
group
tabl
ljee
treatment
attenu
hepat
mda
level
mcddfed
mice
dosedepend
manner
tabl
hepat
mda
level
mcddfed
mice
also
decreas
ciprofibr
treatment
tabl
hepat
mrna
express
level
mcddfed
mice
increas
respect
compar
mcsdfed
group
tabl
howev
treatment
mcddfed
mice
ljee
mgkgday
reduc
hepat
mrna
express
rel
express
level
vehicletr
mcddfed
mice
tabl
treatment
mcddfed
mice
ciprofibr
reduc
hepat
mrna
express
rel
vehicletr
mcddfed
mice
tabl
compar
mcsdfed
group
hepat
mrna
level
collagen
mcddfed
mice
increas
obvious
respect
tabl
downregul
ljee
mgkgday
treatment
decreas
respect
tabl
hepat
mrna
level
collagen
mcddfed
mice
receiv
ciprofibr
treatment
decreas
rel
express
level
vehicletr
counterpart
respect
tabl
hepat
mrna
level
significantli
reduc
ljee
mgkgday
treat
mcddfed
mice
compar
vehicletr
counterpart
tabl
ciprofibr
suppress
mcddinduc
stimul
hepat
mrna
level
rel
vehicletr
counterpart
tabl
mrna
level
liver
mcddfed
mice
lower
mscdfed
group
tabl
hepat
mrna
level
upregul
ljee
mgkgday
ciprofibr
treatment
increas
compar
observ
vehicletr
counterpart
tabl
consider
alter
observ
phosphoryl
form
erk
among
mcddfed
mice
rel
mcsdfed
group
treatment
mcddfed
mice
ljee
result
signific
increas
extent
erk
phosphoryl
figur
similar
result
obtain
ciprofibratetr
mcddfed
group
figur
jnk
phosphoryl
significantli
greater
liver
mcddfed
mice
compar
mcsdfed
group
figur
ljee
mgkgday
treat
mcddfed
mice
lower
jnk
phosphoryl
liver
vehicletr
counterpart
figur
ciprofibr
suppress
hepat
jnk
phosphoryl
mcddfed
mice
rel
vehicletr
counterpart
figur
chang
observ
phosphoryl
liver
mcddfed
mice
compar
mcsdfed
group
figur
treatment
mcddfed
mice
ljee
ciprofibr
affect
phosphoryl
liver
figur
alter
total
hepat
erk
jnk
andor
content
occur
among
differ
group
figur
tabl
effect
hepat
mrna
express
nashrel
specif
gene
mcsdor
mcddfed
mice
receiv
four
week
treatment
vehicl
distil
water
use
prepar
test
medic
solut
given
volum
valu
obtain
group
eight
anim
group
four
week
experiment
period
p
b
p
compar
valu
vehicletr
mcddfed
mice
group
respect
histopatholog
featur
nash
includ
evid
steatosi
liver
cell
injuri
mix
inflammatori
lobular
infiltr
variabl
degre
fibrosi
mcdd
wellestablish
widelyus
nutrit
model
steatohepat
caus
hepat
steatosi
inflamm
mimic
nafld
human
studi
mice
consist
develop
steatosi
balloon
injuri
inflammatori
cell
infiltr
follow
mcdd
intak
line
previou
report
nutrit
model
nash
histopatholog
find
liver
mcdd
fedmic
consider
amelior
ljee
treatment
also
found
alt
ast
activ
markedli
reduc
mcdd
fedmic
treat
ljee
ast
alt
consid
sensit
indic
hepatocellular
damag
within
limit
provid
quantit
evalu
degre
damag
liver
result
indic
ljee
attenu
liver
injuri
mcddinduc
nash
anim
model
histopatholog
featur
nash
includ
evid
steatosi
liver
cell
injuri
mix
inflammatori
lobular
infiltr
variabl
degre
fibrosi
mcdd
wellestablish
widelyus
nutrit
model
steatohepat
caus
hepat
steatosi
inflamm
mimic
nafld
human
studi
mice
consist
develop
steatosi
balloon
injuri
inflammatori
cell
infiltr
follow
mcdd
intak
line
previou
report
nutrit
model
nash
histopatholog
find
liver
mcdd
fedmic
consider
amelior
ljee
treatment
also
found
alt
ast
activ
markedli
reduc
mcdd
fedmic
treat
ljee
ast
alt
consid
sensit
indic
hepatocellular
damag
within
limit
provid
quantit
evalu
degre
damag
liver
result
indic
ljee
attenu
liver
injuri
mcddinduc
nash
anim
model
fat
accumul
liver
recogn
first
hit
pathogenesi
nash
found
ljee
produc
pharmaceut
effect
hepat
cholesterol
tg
level
sever
studi
suggest
hepat
lipogenesi
increas
hepat
steatosi
may
result
either
increas
tg
synthesi
decreas
fatti
acid
oxid
lead
increas
tg
content
liver
microsom
enzym
join
acylcoa
thu
constitut
final
step
tg
biosynthesi
although
mcdd
promot
intrahepat
lipid
accumul
impair
verylowdens
lipoprotein
vldl
secret
mrna
encod
gene
relat
lipogenesi
suppress
mice
fed
mcdd
agreement
find
result
show
express
mcddfed
mice
also
decreas
ljeetreat
group
result
demonstr
ljee
induc
downregul
lipogenesisrel
gene
inhibit
accumul
hepat
lipid
droplet
via
decreas
tg
synthesi
mcddfed
mice
microsom
tg
transfer
protein
mttp
respons
vldl
assembl
export
liver
probabl
contribut
derang
triglycerid
metabol
howev
reduc
mttp
express
found
variou
mous
model
nash
direct
studi
need
assess
whether
ljee
alter
would
suffic
correct
defect
addit
mrna
level
significantli
increas
ljeetreat
mcddfed
mice
play
central
role
uptak
fatti
acid
especi
liver
report
protect
mcdd
highfatinduc
nash
rodent
benefici
effect
ljee
treatment
liver
steatosi
may
partli
due
enhanc
fatti
acid
oxid
liver
hepat
steatosi
increas
liver
suscept
seriou
insult
like
inflamm
increas
oxid
stress
especi
presenc
oxidiz
unsatur
fatti
acid
steatot
liver
oxid
unsatur
fatti
acid
increas
lipid
peroxid
activ
hepat
stellat
cell
thu
expedit
develop
fibrosi
member
oxidoreductas
cytochrom
famili
oxid
varieti
small
molecul
substrat
includ
xenobiot
ethanol
fatti
acid
express
activ
liver
increas
human
anim
model
nafld
consid
critic
hit
transit
benign
steatosi
steatohepat
work
ljee
treatment
suppress
express
reduc
hepat
mda
level
marker
lipid
peroxid
mcddfed
mice
indic
treatment
ljee
could
abat
mcddinduc
oxid
stress
liver
accord
two
hit
theori
pathogenesi
nash
reactiv
oxygen
product
increas
second
hit
caus
accumul
lipid
peroxid
product
mitochondri
dysfunct
increas
secret
proinflammatori
cytokin
inflammatori
cytokin
play
major
role
progress
steatosi
nash
caus
secret
variou
cytokin
chemokin
among
secret
cytokin
import
one
play
pivot
role
hepat
fibrogenesi
hepat
stellat
cell
hsc
activ
hsc
activ
result
express
deposit
collagen
also
modul
sever
matrix
metalloproteinas
involv
liver
injuri
repair
remodel
relev
mmp
regard
liver
diseas
present
studi
demonstr
ljee
lower
mrna
level
hepat
otherwis
higher
follow
mcdd
feed
increas
express
variou
extracellular
matrixrel
factor
collagen
liver
mcdd
fed
mice
also
diminish
ljee
treatment
result
present
research
suggest
attenu
second
hit
ljee
improv
liver
inflamm
fibrosi
induc
mcdd
activ
regulatori
mitogenactiv
protein
kinas
mapk
jnk
phosphoryl
usual
lead
cell
death
inflamm
increas
jnk
phosphoryl
report
nash
model
mice
wherea
pathway
remain
unaffect
mcdd
data
full
agreement
publish
report
demonstr
mcdd
led
higher
phosphoryl
jnk
treatment
ljee
decreas
jnk
phosphoryl
nash
model
mice
although
inhibit
activ
show
clear
associ
benefit
effect
ljee
attenu
hyperglycemiaaffect
renal
dysfunct
data
show
activ
affect
neither
mcdd
ljee
administr
addit
report
erk
mapk
pathway
involv
mcddinduc
nash
howev
activ
report
decreas
express
erk
activ
probabl
requir
treatment
diseas
studi
demonstr
ljee
increas
extent
erk
phosphoryl
may
lead
increas
regener
liver
reduc
fat
accumul
inflamm
decreas
express
proinflammatori
cytokin
chemokin
nash
result
suggest
inhibitori
effect
ljee
develop
progress
nash
appar
govern
augment
erk
activ
attenu
jnk
activ
hepatoprotect
effect
ljee
mcddinduc
nash
seem
effect
produc
ciprofibr
indic
dosag
compound
isol
identifi
l
japonica
far
specif
activ
constitu
ljee
respons
hepatoprotect
effect
remain
identifi
futur
research
data
suggest
ljee
prevent
hepat
steatosi
reduc
hepat
express
well
induc
express
addit
data
suggest
ljee
inhibit
develop
hepat
inflamm
fibrosi
suppress
sever
inflammatori
molecul
inhibitori
effect
ljee
nash
result
jnk
inhibit
increas
activ
erk
ljee
may
option
nash
prevent
treatment
